Show simple item record

dc.contributor.authorLirussi, Darío
dc.contributor.authorEbensen, Thomas
dc.contributor.authorSchulze, Kai
dc.contributor.authorReinhard, Elena
dc.contributor.authorTrittel, Stephanie
dc.contributor.authorRiese, Peggy
dc.contributor.authorProchnow, Blair
dc.contributor.authorGuzmán, Carlos A.
dc.date.accessioned2018-11-16T14:40:58Z
dc.date.available2018-11-16T14:40:58Z
dc.identifier.issn1940-087X
dc.identifier.doi10.3791/57401
dc.identifier.urihttp://hdl.handle.net/10033/621571
dc.description.abstractThe assessment of modern sub-unit vaccines reveals that the generation of neutralizing antibodies is important but not sufficient for adjuvant selection. Therefore, adjuvants with both humoral and cellular immuno-stimulatory capabilities that are able to promote cytotoxic T lymphocytes (CTL) responses are urgently needed. Thus, faithful monitoring of adjuvant candidates that induce cross-priming and subsequently enhance CTL generation represents a crucial step in vaccine development. In here we present an application for a method that uses SIINFEKL-specific (OT-I) T cells to monitor the cross-presentation of the model antigen ovalbumin (OVA) in vivo in the presence of different adjuvant candidates. This method represents a rapid test to select adjuvants with the best cross-priming capabilities. The proliferation of CD8+ T cells is the most valuable indication of cross-priming and it is also regarded as a correlate of adjuvant-induced cross-presentation. This feature can be evaluated in different immune organs like lymph nodes and spleen. The extent of the CTL generation can also be monitored, thereby giving insights on the nature of a local (draining lymph node mainly) or a systemic response (distant lymph nodes and/or spleen). This technique further allows multiple modifications for testing drugs that can inhibit specific cross-presentation pathways and also offers the possibility to be used in different strains of conventional and genetically modified mice. In summary, the application that we present here will be useful for vaccine laboratories in industry or academia that develop or modify chemical adjuvants for vaccine research and development. © 2018, Journal of Visualized Experiments.en_US
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/ 730964en_US
dc.relation.urlhttps://www.jove.com/video/57401/rapid-vivo-assessment-adjuvant-s-cytotoxic-t-lymphocytes-generationen_US
dc.rightsembargoedAccessen_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.titleRapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Developmenten_US
dc.typeArticleen_US
dc.contributor.departmentHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.en_US
dc.source.issue136
dc.source.journaltitleJournal of Visualized Experiments


Files in this item

Thumbnail
Name:
Lirussi et al.pdf
Size:
291.0Kb
Format:
PDF
Description:
original manuscript
Thumbnail
Name:
Figures-Table Rapid In Vivo ...
Size:
7.490Mb
Format:
Microsoft PowerPoint 2007
Description:
figurs and tables to Lirussi et al.

This item appears in the following Collection(s)

Show simple item record

embargoedAccess
Except where otherwise noted, this item's license is described as embargoedAccess